Critiques of clinical guidelines in nephrology: Anaemia

Nephron - Clinical Practice

Volumn 110, Issue 2, 2008, Pages

  Courtney, A E ^a   Maxwell, A P ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Clinical practice guidelines; Erythropoiesis stimulating agents; Erythropoietin

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; ECHOCARDIOGRAPHY; HEALTH CARE COST; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME;

ANEMIA; GREAT BRITAIN; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 53849087883     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163844     Document Type: Short Survey

References (58)

1. Erslev AJ: Erythropoietin. N Engl J Med 1991;324:1339-1344.
2. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-381.
3. Fried W: Hematologic complications of chronic renal failure. Med Clin North Am 1978;62:1363-1379.
4. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825-830.
5. Macdougall IC: Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-207.
6. US Renal Data System Annual Data Report. Bethesda, National Institute of Health, 2006. Available at: www.usrds.org/adr_2006.htm.
7. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388.
8. Clinical Practice Guidelines Module 2: Complications. UK Renal Association. Available at: www.renal.org/guidelines.
9. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
10. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(5 suppl 3):S11-S145.
11. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
12. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14(suppl 5):1-50.
13. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA): US Food and Drug Administration Information for Healthcare, Center for Drug Evaluation and Research. Public Health Advisory. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm.
14. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
15. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991;6:31-37.
16. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998;13:1642-1644.
17. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
18. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473.
19. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-1914.
20. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
21. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
22. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803-1810.
23. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D: Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006;17:2293-2298.
24. Strippoli GF, Craig JC, Manno C, Schena FP: Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004;15:3154-3165.
25. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
26. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-361.
27. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
28. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-2189.
29. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
30. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
31. Remuzzi G, Ingelfinger JR: Correction of anemia - payoffs and problems. N Engl J Med 2006;355:2144-2146.
32. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA: Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-413.
33. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, de Alvaro F: Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007;49:194-207.
34. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148-156.
35. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811.
36. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dl. Kidney Int 2005;68:788-795.
37. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-185.
38. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760.
39. Strippoli GF, Navaneethan SD, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006:CD003967.
40. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403-3410.
41. Courtney AE, McNamee PT, Maxwell AP: Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients. Nephron Clin Pract 2007;107:c14-c19.
42. Annual Reports: UK Renal Registry. Available at: www.renalreg.com.
43. Lappin TR, Maxwell AP, Johnston PG: Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 2007;12:362-365.
44. Hodges VM, Rainey S, Lappin TR, Maxwell AP: Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 2007;64:139-158.
45. Crawford J: Erythropoietin: high profile, high scrutiny. J Clin Oncol 2007;25:1021-1023.
46. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
47. Fishbane S: Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1-4.
48. Lappin TR, Maxwell AP, Johnston PG: EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002;20:485-492.
49. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR: Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 2006;3:94-100.
50. Atlas of End-Stage Renal Disease in the United State: Medicare Expenditures: USRDS 2007 Annual Report. Available at: http://www.usrds.org/2007/ pdf/00a_precis_07.pdf.
51. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003;64:295-304.
52. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF Jr: Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002;13:1288-1295.
53. Hynes DM, Stroupe KT, Kaufman JS, Reda DJ, Peterman A, Browning MM, Huo Z, Sorbara D: Adherence to guidelines for ESRD anemia management. Am J Kidney Dis 2006;47:455-461.
54. Ingelfinger JR: Through the looking glass: anemia guidelines, vested interests, and distortions. Clin J Am Soc Nephrol 2007;2:415-417.
55. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-124.
56. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343.
57. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170.
58. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-138.